Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/12/24
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 10/08/22
End: 12/30/26
Due: 12/30/27
Phase: N/A
Priority: Normal
Start: 05/27/22
End: 12/30/25
Due: 12/30/26
Phase: N/A
Priority: Normal
Start: 12/01/20
End: 12/30/25
Due: 12/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. | NCT06655662 | Shenzhen Hemogen | user2@example.com | None | 2024-06-12 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia | NCT05851105 | Shenzhen Hemogen | user2@example.com | None | 2022-10-08 | 2026-12-30 | 2027-12-30 | - | - | 2025-07-14 |
| the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia | NCT05864170 | Shenzhen Hemogen | user2@example.com | None | 2022-05-27 | 2025-12-30 | 2026-12-30 | - | - | 2025-07-14 |
| Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients | NCT05745532 | Shenzhen Hemogen | user2@example.com | None | 2020-12-01 | 2025-12-30 | 2026-12-30 | - | - | 2025-07-14 |